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A trans-ethnic meta-analysis of type 2 diabetes genome-wide association studies has identi-
fied seven novel susceptibility variants in or near TMEM154, SSR1/RREB1, FAF1, POU5F1/
TCF19, LPP, ARL15 and ABCB9/MPHOSPH9. The aim of our study was to investigate asso-
ciations between these novel risk variants and type 2 diabetes and pre-diabetic traits in a
Danish population-based study with measurements of plasma glucose and serum insulin
after an oral glucose tolerance test in order to elaborate on the physiological impact of
the variants.
Methods
Case-control analyses were performed in up to 5,777 patients with type 2 diabetes and
7,956 individuals with normal fasting glucose levels. Quantitative trait analyses were per-
formed in up to 5,744 Inter99 participants naïve to glucose-lowering medication. Significant
associations between TMEM154-rs6813195 and the beta cell measures insulinogenic
index and disposition index and between FAF1-rs17106184 and 2-hour serum insulin levels
were selected for further investigation in additional Danish studies and results were com-
bined in meta-analyses including up to 6,486 Danes.
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Results
We confirmed associations with type 2 diabetes for five of the seven SNPs (TMEM154-
rs6813195, FAF1-rs17106184, POU5F1/TCF19-rs3130501, ARL15-rs702634 and ABCB9/
MPHOSPH9-rs4275659). The type 2 diabetes risk C-allele of TMEM154-rs6813195 associ-
ated with decreased disposition index (n=5,181, β=-0.042, p=0.012) and insulinogenic
index (n=5,181, β=-0.032, p=0.043) in Inter99 and these associations remained significant
in meta-analyses including four additional Danish studies (disposition index n=6,486,
β=-0.042, p=0.0044; and insulinogenic index n=6,486, β=-0.037, p=0.0094). The type 2 dia-
betes risk G-allele of FAF1-rs17106184 associated with increased levels of 2-hour serum in-
sulin (n=5,547, β=0.055, p=0.017) in Inter99 and also when combining effects with three
additional Danish studies (n=6,260, β=0.062, p=0.0040).
Conclusion
Studies of type 2 diabetes intermediary traits suggest the diabetogenic impact of the C-
allele of TMEM154-rs6813195 is mediated through reduced beta cell function. The impact
of the diabetes risk G-allele of FAF1-rs17106184 on increased 2-hour insulin levels is
however unexplained.
Introduction
About 90 genomic loci harboring genetic variation increasing the risk of developing type 2 dia-
betes (T2D) have been identified mostly by genome-wide association studies (GWAS) [1].
Most large-scale studies have in the past primarily been performed in populations of European
decent, and initial genotyping arrays applied in GWAS were designed to mainly capture com-
mon genetic variation in Europeans. Recently, there has been an increase in GWAS undertaken
in other ethnic groups. This has led to the performance of a multi-ethnic meta-analysis of
GWAS data across different populations [2]. By combining GWAS across ancestries, this study
enhanced fine-mapping resolution of causal variants because of differences in linkage disequi-
librium between populations. Furthermore, this trans-ethnic study had increased power to de-
tect new susceptibility variants as a result of an increased sample size and the authors identified
seven novel T2D risk variants. However, the underlying pathophysiology behind the associa-
tion of these novel variants to T2D is not obvious.
The aim of this study was to investigate the seven novel T2D risk variants discovered in the
trans-ethnic meta-analysis for associations with T2D and pre-diabetic quantitative traits in




In the case-control analyses, individuals with normal fasting glucose and T2D cases were in-
cluded from the Danish population-based studies Inter99 [3], Health 2006 study [4], Health
2008 study [5], the outpatient clinic at Steno Diabetes Center, the ADDITION study [6] and
Vejle Biobank. Anthropometric data of individuals involved in the case-control analyses are
given in S1 Table.
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The study of diabetes-related quantitative traits was performed in the Inter99 cohort and
significant findings (p<0.05) were further analyzed in individuals from the ADIGEN cohort
[7] (obese cases and non-obese controls), the Danish Family study [8] and the Health 2008 co-
hort. Description of the study samples are given in S2 Table and information on anthropo-
metrics and metabolic traits is provided in S3 Table and S4 Table.
Ethical statement
Written informed consent was obtained from all participants and the protocols were in accor-
dance with the Helsinki Declaration. The studies were approved by the Scientific Ethics Com-
mittee of the Capital Region of Denmark (Inter99 KA-98155, Health 2006 KA-20060011,
Health 2008 H-KA-20060011, Steno Diabetes Center KA-95117g, KA-94092g, KA-92071 and
KA-99081, Danish Family KA-93033 and ADIGEN KF-01–389–97) or the Scientific Ethics
Committee of Aarhus County (ADDITION 2000183) or the Scientific Ethics Committee of
Southern Denmark (Vejle Biobank S-20080097).
Metabolic measurements
Participants from Inter99, ADIGEN and Health 2008 without known T2D underwent a 75-g
OGTT with blood sampling in the fasting state (after an overnight fast) and at time points 30
min and 120 min. Participants without known T2D from the Danish Family study underwent
a 4 hour OGTT with frequent blood sampling (at 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 140,
160, 180, 210 and 240 min).
Oral glucose-stimulated early insulin response was reported as the insulinogenic index [9]
whereas the acute insulin response (AIR) simulating intravenous glucose tolerance test
(IVGTT) conditions was estimated by the BIGTT-AIR [10]. Whole-body insulin sensitivity was
estimated by the Matsuda insulin sensitivity index (ISIMatsuda) [11] and the BIGTT-sensitivity
index (SI) [10]. Besides the OGTT-sampled plasma glucose and serum insulin values the
BIGTT indexes apply information on sex and body mass index [10]. Beta cell function corrected
for whole-body insulin sensitivity level was expressed as the disposition index [12]. Detailed in-
formation on metabolic measurements and calculations is provided in S5 Table.
Genotyping
Genotype information on all seven T2D risk variants (TMEM154-rs6813195, SSR1/RREB1-
rs9505118, FAF1-rs17106184, POU5F1/TCF19-rs3130501, LPP-rs6808574, ARL15-rs702634
and ABCB9/MPHOSPH9-rs4275659) was available from the Metabochip (Illumina genotyping
array) [13], and four of the variants (TMEM154-rs6813195, SSR1/RREB1-rs9505118, POU5F1/
TCF19-rs3130501 and ABCB9/MPHOSPH9-rs4275659) had also available genotype informa-
tion from the ExomeBeadChip v1.0 (Illumina genotyping array) [14]. The Inter99, Health
2006 and Steno Diabetes Center cohorts had genotype information from both the Metabochip
and the ExomeBeadChip. In these cohorts, the Metabochip genotyping information was used,
but if genotypes were missing for any of the four SNPs which were genotyped on both arrays,
genotyping information from the ExomeBeadChip was used to supplement where possible.
The Health 2008, ADDITION and Vejle Biobank had genotype information from the Exome-
BeadChip only and the Danish Family study had genotype information from the Metabochip
only. The Metabochip genotype calling and quality control have been described before [15].
ExomeBeadChip genotypes were called using GenCall applying a custom-made cluster file
based on 6000 samples with high quality data. From the ExomeBeadChip, quality control of
samples and variants was done using PLINK and included exclusion of samples showing relat-
edness (first- and second-degree relatives), extreme inbreeding coefficient or mismatch
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between sex status in phenotype and genotype data. Furthermore, we removed individuals
with discordant genotype data between one of the four variants available on both genotype ar-
rays (1.5%). Genotyping quality for each selected variant was assessed by the call-rate (>95%)
and presence of Hardy-Weinberg equilibrium (P>0.0005).
In ADIGEN, genome-wide genotyping on the Illumina 610k quad chip was carried out at
the Centre National deGénotypage (CNG, Evry, France). Quality control and imputation
methods have been described previously [16]. The genotypes of TMEM154-rs6813195 and
FAF1-rs17106184 were extracted with a call-rate of 100%.
Statistical analyses
Analyses in Inter99, Health 2006, Health 2008, ADDITION, Steno Diabetes Center and Vejle
Biobank were performed using RStudio software version 0.98.501 (http://www.rstudio.com).
In the Danish Family study analyses were performed in SOLAR version 6.6.2 and in the ADI-
GEN cohort analyses were performed using the R statistical program version 3.0.2 (http://
www.r-project.org/).
Case-control analyses: T2D associations were tested by logistic regression using an additive
genetic model adjusting for sex and age in up to 5,777 Danish patients with T2D from Inter99
(n = 320), Health 2006 (n = 166), Health 2008 (n = 18), Steno Diabetes Center (n = 1,424), AD-
DITION (n = 1,870) and Vejle Biobank (n = 1,979) and up to 7,956 individuals with normal
fasting glucose from Inter99 (n = 4,590), Health 2006 (n = 2,412), Health 2008 (n = 528) and
Vejle Biobank (n = 426).
Quantitative glycemic trait analyses: Associations between the seven novel T2D risk variants
and quantitative glycemic traits in up to 5,744 Inter99 individuals without patients known to
have T2D were examined by linear regression using additive genetic models adjusting for age
(BIGTT indexes) or age and sex (all other traits). Values of serum insulin, insulinogenic index,
ISIMatsuda, disposition index and BIGTT-AIR were natural log (ln) transformed before analyses.
If beta coefficients were back transformed, it was done by ebeta coefficient and multiplied by 100
to get effect sizes in percent. The case-control and quantitative trait analyses were beside age
and sex also adjusted for BMI in order to obtain estimates independent of adiposity to reduce
extra variance that is not attributable to genetic variation or to reveal potentially adiposity
modulating effects.
The significant findings (p<0.05) from Inter99 were selected for further analyses in the
Health 2008, ADIGEN and Danish Family study cohorts (having OGTT data) where available.
The associations between TMEM154-rs6813195 and both insulinogenic index and disposi-
tion index were therefore performed in 592 individuals from Health 2008, 165 obese cases and
246 controls from ADIGEN and 302 individuals from the Danish Family study. The associa-
tion between FAF1-rs17106184 and 2-hour serum insulin was also performed in these cohorts
except Health 2008, where this variant was not genotyped. The participants from these addi-
tional Danish cohorts were all naïve to glucose lowering medication and the analyses using
Health 2008 and ADIGEN data were performed by linear regression using additive genetic
models adjusting for age, sex and BMI (Health 2008) or age and BMI (ADIGEN). In the 302 in-
dividuals from the Danish Family study the analysis was performed using variance components
with age, sex and BMI as covariates [17]. Values of insulinogenic index, disposition index and
2-hour serum insulin were ln transformed. The beta coefficients and standard errors derived
from the linear regression analyses were then combined in a meta-analysis of up to 6,486 indi-
viduals of which 5,181 individuals are from Inter99. The weight of the studies in the meta-anal-
yses was estimated using inverse variance assuming fixed effects. Heterogeneity was measured
by Q-statistics.
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Bonferroni correction was calculated for 49 independent tests (7 SNPs  7 traits) corre-
sponding to a new statistical significance threshold of 0.001 (0.05/49).
Statistical power was estimated using 1,000 simulations using the RStudio software version
0.98.501. We used the empirical variance of the observed traits in the Inter99 cohort to simu-
late phenotypes from a normal distribution, so that variance across genotypes is drawn from
the estimated variance. We assumed the risk allele frequency of TMEM154-rs6813195 (0.72)
and a significance threshold of 0.05.
Results
Association with T2D
Three out of the seven T2D risk variants nominally associated with T2D in the Danish popula-
tion sample of 5,777 cases and 7,956 controls; the C-allele of TMEM154-rs6813195 (odds ratio
(OR) = 1.09 [95% confidence interval (CI) = 1.02–1.16], p = 0.015), the G-allele of POU5F1/
TCF19-rs3130501 (OR = 1.08 [95% CI = 1.01–1.16], p = 0.030) and the C-allele of
MPHOSPH9-rs4275659 (OR = 1.07 [95% CI = 1.00–1.15], p = 0.047) (Table 1). In addition,
also the G-allele of FAF1-rs17106184 (OR = 1.21 [95% CI = 1.03–1.42], p = 0.019) and the A-
allele of ARL15-rs702634 (OR = 1.12 [95% CI = 1.02–1.25], p = 0.024) associated with T2D
when also adjusting for BMI (Table 1). All seven variants showed the same direction of effect
as originally reported and with comparable odds ratios.
Association with metabolic intermediary quantitative traits
Carriers of the T2D risk C-allele of TMEM154-rs6813195 had a lower disposition index in
Inter99 both in the analysis with (n = 5,181, β = -0.042, p = 0.012) and without adjustments for
BMI (n = 5,182, β = -0.043, p = 0.014) (Table 2). The association remained significant with an
effect size estimate similar to what we observed in Inter99 when combining data from Inter99,
Health 2008, ADIGEN and the Danish Family study in a meta-analysis (n = 6,486, β = -0.042,
p = 0.0044) (Fig. 1). In other words, carriers of the T2D risk C-allele of TMEM154-rs6813195
had on average a 4.1% lower value of the disposition index per C-allele.
We also found a borderline significant association between the C-allele of TMEM154-
rs6813195 and a lower insulinogenic index again both in the analysis with (n = 5,181,
β = -0.032, p = 0.043) and without adjustments for BMI (n = 5,182, β = -0.031, p = 0.052) in
Inter99. In the meta-analysis combining data from Inter99, Health 2008, ADIGEN and the
Table 1. T2D case-control analyses of up to 5,777 patients from Inter99 (n = 320), Health 2006 (n = 166), Health 2008 (n = 18), Steno Diabetes Center
(n = 1,424), ADDITION (n = 1,870) and Vejle Biobank (n = 1,979) and up to 7,956 individuals with normal fasting glucose from Inter99 (n = 4,590),
Health 2006 (n = 2,412), Health 2008 (n = 528) and Vejle Biobank (n = 426).
SNP Function/gene RA RAF n cases vs. n controls OR (95% CI) P ORadjBMI (95% CI) PadjBMI
rs6813195 Intergenic TMEM154 C 0.72 415/2213/3102 vs. 672/3179/4105 1.09 (1.02–1.16) 0.015 1.12 (1.03–1.21) 0.0054
rs9505118 Intron SSR1/RREB1 A 0.59 935/2765/2028 vs. 1318/3920/2716 1.04 (0.98–1.11) 0.21 1.04 (0.97–1.12) 0.25
rs17106184 Intron FAF1 G 0.90 10/350/1516 vs. 69/1295/5447 1.09 (0.95–1.26) 0.23 1.21 (1.03–1.42) 0.019
rs3130501 Intron POU5F1/TCF19 G 0.73 403/2261/3057 vs. 610/3204/4137 1.08 (1.01–1.16) 0.030 1.08 (1.00–1.17) 0.049
rs6808574 Intergenic LPP C 0.63 224/856/739 vs. 881/3173/2517 1.05 (0.95–1.15) 0.33 1.05 (0.94–1.16) 0.39
rs702634 Intron ARL15 A 0.69 172/775/929 vs. 686/2884/3239 1.08 (0.99–1.19) 0.09 1.12 (1.02–1.25) 0.024
rs4275659 Intron ABCB9/ MPHOSPH9 C 0.72 433/2216/3082 vs. 640/3201/4115 1.07 (1.00–1.15) 0.047 1.06 (0.99–1.15) 0.11
Number of cases vs. number of controls is shown as 0/1/2 risk alleles. Odds ratios (OR) and P-values (P) are adjusted for age and sex. ORadjBMI and
PadjBMI are adjusted for age, sex and BMI. SNP, single nucleotide polymorphism. RA, risk allele. RAF, risk allele frequency. CI, conﬁdence interval.
doi:10.1371/journal.pone.0120890.t001
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Table 2. Associations between the seven T2D risk variants and quantitative traits in up to 5,744 Danish individuals naive to glucose-lowering
medication.
TMEM154 rs6813195 TT TC CC Effect SE P PadjBMI
n (% men/women) 469 (46/54) 2,281 (51/49) 2,994 (49/51)
Age (years) 45 (40–50) 45 (40–50) 45 (40–50)
BMI (kg/m2) 26 (23–28) 26 (23–28) 26 (23–29) 0.001 0.003 0.74 -
30-min insulin (pmol/l) 251 (177–357) 252 (176–358) 243 (173–352) -0.010 0.012 0.39 0.32
2-hour insulin (pmol/l) 165 (99–264) 151 (92–252) 159 (99–259) 0.015 0.017 0.36 0.31
Insulinogenic index 77.1 (46.3–126.0) 74.0 (46.1–119.9) 69.0 (43.9–117.0) -0.031 0.016 0.052 0.043
ISIMatsuda 7.6 (5.2–11.0) 7.9 (5.2–11.3) 7.7 (5.1–11.3) -0.009 0.013 0.49 0.64
Disposition index 546 (319–986) 547 (333–948) 518 (313–877) -0.043 0.017 0.014 0.012
BIGTT-SI 9.2 ± 3.9 9.3 ± 4.1 9.2 ± 4.1 -0.014 0.088 0.87 -
BIGTT-AIR 1,656 (1,288–2,163) 1,642 (1,305–2,085) 1,613 (1,277–2,069) -0.010 0.009 0.27 -
SSR1/RREB1 rs9505118 GG GA AA Effect SE P
n (% men/women) 957 (50/50) 2,804 (50/50) 1,982 (49/51)
Age (years) 45 (40–50) 45 (40–50) 45 (40–50)
BMI (kg/m2) 26 (23–28) 26 (23–29) 26 (23–28) 0.000 0.003 0.90 -
30-min insulin (pmol/l) 254 (176–360) 246 (175–353) 244 (174–354) -0.002 0.011 0.82 0.79
2-hour insulin (pmol/l) 155 (96–265) 158 (97–253) 155 (98–256) 0.004 0.015 0.79 0.83
Insulinogenic index 73.3 (45.5–120.2) 71.1 (44.7–115.7) 71.3 (44.5–122.6) 0.003 0.015 0.85 0.87
ISIMatsuda 7.8 (5.2–10.9) 7.7 (5.2–11.3) 7.9 (5.2–11.4) 0.008 0.012 0.52 0.35
Disposition index 532 (321–898) 525 (316–902) 544 (326–940) 0.007 0.016 0.68 0.69
BIGTT-SI 9.2 ± 4.0 9.2 ± 4.1 9.3 ± 4.0 0.019 0.081 0.82 -
BIGTT-AIR 1,643 (1,295–2,042) 1,623 (1,284–2,078) 1,630 (1,279–2,097) 0.005 0.009 0.53 -
FAF1 rs17106184 AA AG GG Effect SE P
n (% men/women) 53 (60/40) 1,068 (47/53) 4,506 (50/50)
Age (years) 45 (40–55) 45 (40–50) 45 (40–50)
BMI (kg/m2) 26 (24–28) 26 (23–29) 26 (23–28) -0.006 0.005 0.24 -
30-min insulin (pmol/l) 247 (185–300) 253 (175–364) 245 (175–354) -0.008 0.018 0.65 0.88
2-hour insulin (pmol/l) 132 (92–287) 150 (93–248) 159 (98–257) 0.046 0.025 0.07 0.017
Insulinogenic index 65.4 (43.1–108.2) 72.6 (45.6–123.0) 71.4 (44.7–118.7) -0.008 0.024 0.73 0.85
ISIMatsuda 7.7 (5.2–9.8) 7.8 (5.1–11.3) 7.8 (5.2–11.3) 0.006 0.019 0.73 0.64
Disposition index 508 (279–882) 528 (333–908) 535 (318–909) -0.003 0.026 0.90 0.69
BIGTT-SI 8.9 ± 3.4 9.3 ± 4.0 9.2 ± 4.1 -0.020 0.133 0.88 -
BIGTT-AIR 1,558 (1,448–2,028) 1,637 (1,295–2,077) 1,627 (1,283–2,080) 0.006 0.014 0.68 -
POU5F1/TCF19 rs3130501 AA AG GG Effect SE P
n (% men/women) 434 (52/48) 2,263 (49/51) 3,045 (50/50)
Age (years) 45 (40–55) 45 (40–50) 45 (40–50)
BMI (kg/m2) 26 (24–29) 25 (23–28) 26 (23–29) -0.002 0.003 0.51 -
30-min insulin (pmol/l) 262 (185–357) 241 (175–342) 248 (173–360) -0.011 0.012 0.37 0.56
2-hour insulin (pmol/l) 159 (97–264) 154 (95–251) 158 (98–260) 0.009 0.017 0.58 0.43
Insulinogenic index 70.0 (45.4–116.7) 71.4 (44.6–117.5) 71.8 (44.7–120.0) -0.001 0.016 0.93 1.00
ISIMatsuda 7.4 (5.2–10.5) 7.8 (5.2–73.0) 7.8 (5.2–11.3) 0.011 0.013 0.38 0.48
Disposition index 518 (315–800) 536 (321–927) 532 (322–918) 0.005 0.018 0.77 0.91
BIGTT-SI 8.8 ± 3.8 9.3 ± 4.1 9.2 ± 4.0 0.016 0.089 0.86 -
BIGTT-AIR 1,635 (1,295–2,166) 1,639 (1,290–2,079) 1,622 (1,281–2,074) -0.007 0.009 0.47 -
LPP rs6808574 TT TC CC Effect SE P
n (% men/women) 720 (49/51) 2,634 (51/49) 2,098 (49/51)
Age (years) 45 (40–50) 45 (40–50) 45 (40–50)
(Continued)
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Danish Family study the association with insulinogenic index also remained significant with a
similar effect size estimate (n = 6,486, β = -0.037, p = 0.0094) (Fig. 2). This corresponds to an
average lower value of insulinogenic index of 3.6% per C-allele in TMEM154-rs6813195 C-
allele carriers.
Furthermore, carriers of the T2D risk G-allele of FAF1-rs17106184 had an increased level of
serum insulin 2 hours after an oral glucose challenge when the analysis was adjusted for BMI
(n = 5,547, β = 0.055, p = 0.017). When this association was tested in ADIGEN and the Danish
Family study and results were combined in a meta-analysis, it also remained significant with a
similar effect size estimate (n = 6,260, β = 0.062, p = 0.0040) (Fig. 3). This means that carries of
the FAF1-rs17106184 G-allele on average had a 6.4% higher level of 2-hour insulin per G-allele.
We did not find any associations between the remaining five T2D risk variants and the
Table 2. (Continued)
TMEM154 rs6813195 TT TC CC Effect SE P PadjBMI
BMI (kg/m2) 25 (23–28) 26 (23–29) 26 (23–28) -0.001 0.003 0.74 -
30-min insulin (pmol/l) 250 (171–363) 247 (176–356) 243 (176–353) -0.001 0.011 0.96 0.96
2-hour insulin (pmol/l) 159 (95–263) 157 (98–262) 156 (97–248) -0.007 0.016 0.67 0.72
Insulinogenic index 73.0 (45.3–121.9) 70.9 (44.1–120.4) 71.6 (45.8–116.1) -0.009 0.016 0.55 0.60
ISIMatsuda 7.5 (5.1–11.2) 7.8 (5.1–11.2) 7.8 (5.3–11.4) 0.016 0.012 0.19 0.23
Disposition index 510 (320–902) 531 (314–921) 539 (327–900) 0.007 0.017 0.69 0.77
BIGTT-SI 9.2 ± 4.1 9.1 ± 4.1 9.3 ± 4.0 0.074 0.086 0.39 -
BIGTT-AIR 1,651 (1,301–2,131) 1,627 (1,270–2,073) 1,621 (1,296–2,072) -0.010 0.009 0.29 -
ARL15 rs702634 GG GA AA Effect SE P
n (% men/women) 523 (50/50) 2,419 (49/51) 2,684 (51/49)
Age (years) 45 (40–50) 45 (40–50) 45 (40–50)
BMI (kg/m2) 26 (23–29) 26 (23–29) 26 (23–28) -0.005 0.003 0.13 -
30-min insulin (pmol/l) 257 (174–349) 244 (174–354) 247 (176–359) 0.003 0.012 0.81 0.40
2-hour insulin (pmol/l) 152 (96–251) 157 (97–256) 156 (96–256) 0.014 0.017 0.41 0.16
Insulinogenic index 72.3 (45.5–119.1) 71.2 (44.7–120.5) 71.4 (44.7–117.6) -0.014 0.016 0.39 0.51
ISIMatsuda 8.0 (5.4–11.3) 7.8 (5.2–11.1) 7.7 (5.1–11.4) -0.005 0.012 0.68 0.19
Disposition index 573 (337–957) 542 (322–902) 516 (317–908) -0.019 0.017 0.26 0.12
BIGTT-SI 9.3 ± 4.1 9.1 ± 4.0 9.2 ± 4.1 -0.030 0.087 0.73 -
BIGTT-AIR 1,661 (1,311–2,065) 1,623 (1,293–2,085) 1,622 (1,272–2,075) -0.007 0.009 0.47 -
MPHOSPH9 rs4275659 TT TC CC Effect SE P
n (% men/women) 462 (47/53) 2,265 (50/50) 3,017 (50/50)
Age (years) 45 (40–50) 45 (40–50) 45 (40–50)
BMI (kg/m2) 25 (23–28) 26 (23–29) 26 (23–29) 0.002 0.003 0.63 -
30-min insulin (pmol/l) 244 (178–359) 243 (176–352) 249 (173–358) -0.007 0.012 0.55 0.32
2-hour insulin (pmol/l) 154 (94–260) 156 (97–254) 157 (97–256) 0.014 0.017 0.41 0.47
Insulinogenic index 70.3 (44.3–119.8) 71.0 (45.3–117.5) 72.2 (44.7–119.3) -0.005 0.016 0.77 0.65
ISIMatsuda 8.0 (5.1–11.5) 7.9 (5.2–11.3) 7.7 (5.2–11.2) -0.014 0.013 0.25 0.32
Disposition index 570 (335–961) 532 (316–908) 528 (323–907) -0.018 0.017 0.31 0.44
BIGTT-SI 9.4 ± 4.1 9.2 ± 4.1 9.1 ± 4.0 -0.127 0.088 0.15 -
BIGTT-AIR 1,615 (1,265–2,080) 1,627 (1,277–2,077) 1,632 (1,300–2,086) 0.006 0.009 0.52 -
Raw data are mean±SD or median (interquartile range) and are stratiﬁed according to genotype. Values of serum insulin and derived indexes of
insulinogenic index, ISIMatsuda, disposition index and BIGTT-AIR were natural logarithmical (ln) transformed before analysis. Effects represent beta
coefﬁcients and are shown for the T2D risk allele. P-values (P) are adjusted for age (BIGTT-AIR and BIGTT-SI) or sex and age (all other traits). PadjBMI are
P-values adjusted for age, sex and BMI. All analyses assume an additive genetic model. SE, standard error.
doi:10.1371/journal.pone.0120890.t002
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diabetes-related traits (30-min serum insulin, 2-hour serum insulin, insulinogenic index,
ISIMatsuda, disposition index, BIGTT-SI and BIGTT-AIR).
Discussion
In most large populations used for genome-wide association studies, only measures of fasting
plasma glucose and fasting serum insulin levels are available, making it difficult to link suscep-
tibility SNPs with a detailed pre-diabetic quantitative phenotype. For some of the SNPs,
Fig 1. Meta-analysis of the effect of the C-allele of TMEM154-rs6813195 on disposition index in 6,486 individuals from the Inter99 study (n = 5,181),
Health 2008 study (n = 592), ADIGEN controls (n = 246), ADIGEN obese cases (n = 165) and Danish Family study (n = 302).Gray diamond represents
combined change per risk allele and the 95% confidence interval. Gray squares represent effects size estimates (beta coefficients) in single studies sized
according to their weight in the meta-analyses. The horizontal lines through the gray squares represent the 95% confidence interval. ob, obese. p, P-value.
CI, confidence interval. W(fixed), study weight in the fixed effect meta-analysis.
doi:10.1371/journal.pone.0120890.g001
Fig 2. Meta-analysis of the effect of the C-allele of TMEM154-rs6813195 on insulinogenic index in 6,486 individuals from the Inter99 study
(n = 5,181), Health 2008 study (n = 592), ADIGEN controls (n = 246), ADIGEN obese cases (n = 165) and Danish Family study (n = 302).Gray diamond
represents combined change per risk allele and the 95% confidence interval. Gray squares represent effects size estimates (beta coefficients) in single
studies sized according to their weight in the meta-analyses. The horizontal lines through the gray squares represent the 95% confidence interval. ob, obese.
p, P-value. CI, confidence interval. W(fixed), study weight in the fixed effect meta-analysis.
doi:10.1371/journal.pone.0120890.g002
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follow-up studies in smaller populations with more elaborated measures of glycemic traits have
proposed an underlying physiological phenotype [18]. In this study we investigated the effect
of seven novel T2D risk variants on surrogate measures of beta cell function and insulin sensi-
tivity in order to elaborate on their cause of disease association. We found associations between
a metabolic intermediate trait and two out of the seven T2D risk variants (TMEM154-
rs6813195 and FAF1-rs17106184).
Carriers of TMEM154-rs6813195 C-allele had on average a decreased disposition index in
the Inter99 cohort. The relationship between insulin sensitivity and insulin secretion is thought
to be approximately hyperbolic so that the product of the two variables is constant for individu-
als with the same degree of glucose tolerance [12]. This constant is known as the disposition
index and is thus an indication of the ability of the beta cells to respond appropriately to the
level of insulin resistance. A low value of the disposition index can be caused by a continual ex-
posure to triggers of insulin resistance (e.g. high fat diet or lack of exercise) without beta cell
compensation and results in the progression to pre-diabetes or even to overt T2D. When we
further examined the association between TMEM154-rs6813195 and disposition index in the
additional smaller cohorts, we found the same direction of effect. The variant also showed a
borderline significant association with decreased insulinogenic index in Inter99 and with the
same direction of effect in the meta-analysis. The insulinogenic index is a ratio relating en-
hancement of circulating insulin to magnitude of corresponding glycemic stimulus and is thus
a measure of early insulin response [9]. This observation supports the suggestive negative role
of TMEM154-rs6813195 on beta cell function. The TMEM154-rs6813195 did not associate
with any fasting glycemic traits in the MAGIC consortium [2].
TMEM154 codes for a transmembrane protein, showing ubiquitous mRNA expression
highest in B lymphocytes (Human geneAtlas [19]) but immunohistochemical staining of
human gastrointestinal tract shows strong cytoplasmic and membranous positivity of
TMEM154 in glandular cells of the digestive tract including the duodenum (The Human Pro-
tein Atlas [20]). If these glandular cells are of enteroendocrine character, it can be suggested
Fig 3. Meta-analysis of the effect of the G-allele of FAF1-rs17106184 on 2-hour serum insulin in 6,260
individuals from the Inter99 study (n = 5,547), ADIGEN controls (n = 246), ADIGEN obese cases
(n = 165) and Danish Family study (n = 302).Gray diamond represents combined change per risk allele
and the 95% confidence interval. Gray squares represent effects size estimates (beta coefficients) in single
studies sized according to their weight in the meta-analyses. The horizontal lines through the gray squares
represent the 95% confidence interval. ob, obese. p, P-value. CI, confidence interval. W(fixed), study weight
in the fixed effect meta-analysis.
doi:10.1371/journal.pone.0120890.g003
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that the variant near TMEM154 therefore might have an effect on intestinal secretion of hor-
mones affecting pancreatic beta cells. If this is the case and the variant has an effect on secretion
of hormones such as incretin hormones, then the effect would be observed by an OGTT and
not by an IVGTT. In our data this variant does not associate with BIGTT-AIR, which is a mea-
sure of insulin release simulating IVGTT conditions, fitting well to the suggestive interpreta-
tion of data. However, the fact that we do not observe an association with BIGTT-AIR can also
be due to lack of statistical power.
Carriers of FAF1-rs17106184 G-allele had on average an increased level of insulin 2 hours
after a glucose challenge. A neighbouring gene to FAF1 is ELAVL4 (also calledHuD), which is
expressed in the pancreas. The product ofHuD binds to insulin mRNA 5’-UTR and represses
translation of insulin [21]. If FAF1-rs17106184 has a negative effect on expression ofHuD, this
could result in a decreased repression of insulin translation and therefore in more insulin being
produced and later also released explaining the observed increased insulin levels. It is however
unexpected that the T2D risk allele associates with increased insulin secretion, when it does not
seem to associate with increased insulin resistance either in our or MAGIC consortium data [2].
When interpreting our results it should be noticed that if P-values were corrected for testing
seven SNPs and seven traits, none of the observed associations would remain significant. This
is however a very stringent correction, since the seven traits are highly correlated. This study is
a cross-sectional study and the associations found here are related to a certain time-point and
have a poor clinical value like the rest of the T2D-associated variants identified by GWAS due
to their small effect sizes. It is not known if our observed associations could change over time
being more clinical relevant, but so far longitudinal studies of T2D risk prediction including ge-
netic variants have reported similar results to those from cross-sectional studies [22].
Still larger sample sizes are used in meta-analyses of T2D GWAS in order to discover novel
susceptibility loci. In 2012 Morris et al performed a meta-analysis of Metabochip data involv-
ing 34,840 T2D cases and 114,981 controls [23]. In the latest trans-ethnic T2D meta-analysis
this number has increased to 47,979 T2D cases and 139,611 controls [2]. As a consequence the
larger sample size makes it possible to identify T2D risk variants with smaller effect sizes (odds
ratios<1.10). Similarly, the effects of the GWAS-identified variants on quantitative metabolic
traits are likely smaller compared to the risk variants discovered by the first wave of GWAS. In
this study using Inter99 data we generally observed small effect sizes with narrow 95% confi-
dence intervals (often in the range of +/- 0.03 (log-transformed units) around the beta coeffi-
cient except for BIG-SI), indicating that possible true effect sizes likely reflect very small
differences between carriers and non-carriers. The more well-characterized study populations
are often of smaller size and will eventually run out of statistical power to unravel the potential
mechanism of novel variants with very small effects. In the Inter99 cohort we have 80% statisti-
cal power to find per allele effect sizes down to 0.055 for disposition index and down to 0.035
for ISIMatsuda for a common variant with a risk allele frequency of 72%. If the novel variants
have a very small true effect on the trait tested here, the few findings of associations in the pres-
ent study can be explained by low statistical power. Another explanation of the sparse findings
could be that the association signals in these loci inflict risk of T2D by yet unknown pathophys-
iological pathways not measured by the phenotypes we analyzed. It is also possible that the lim-
ited statistical model of this study is the major bottleneck, and that only certain gene-
environment interactions models can reveal the effects of these variants.
In conclusion, if replicated in independent study materials our explorative examinations of
intermediary phenotypes of seven recently discovered T2D genomic risk loci suggest that carri-
ers of the T2D risk C-allele of TMEM154-rs6813195 have a decreased ability to secrete suffi-
cient amount of insulin after an oral glucose load. Furthermore, much larger study materials,
additional and refined phenotyping or novel statistical modeling seem to be needed to detect
Association between TMEM154-rs6813195 and Beta Cell Function
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the pathophysiological implications of newly identified T2D gene variants with modest
effect sizes.
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